Our story

We are an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life-changing treatments for severe lung diseases. Embedded in our approach is the determination to find solutions for conditions which have an enormous deleterious impact on patients and their families and to transform the lives of those affected.

Patients with severe lung diseases can suffer from progressive difficulty in breathing and a relentless deterioration in quality of life. Receiving such a diagnosis can be devastating, due to the poor prognosis. We appreciate that living with such diseases presents a constant challenge, not only for patients but also for their families and caregivers. Our research and drug development programmes are specifically aimed at alleviating these challenges with the patient at the forefront of our minds.

From early days to the present

We were founded in 2000, following research at Uppsala University and the Sahlgrenska Academy, and originally funded by venture capital. In December 2015, the Company completed an equity issue and was publicly listed on Nasdaq First North.

In the summer of 2018, with new Venture Capitalist backing from HealthCap, Vicore Pharma further strengthened its financial position. With the new funding, these transformational medicines can be effectively moved closer to patients. In September 2019 Vicore Pharma listed its shares on Nasdaq Stockholm.

Current development initiatives

Over recent years, we have collaborated with academic institutions to generate extensive efficacy data in preclinical disease models to form the scientific basis of our current clinical initiatives.

Our ongoing drug development programmes are deeply rooted in the complexities of severe lung disease, in particular fibrotic lung disease. At present, there are no highly effective pharmaceutical treatments for conditions such as idiopathic pulmonary fibrosis (IPF) which is associated with a significant morbidity and mortality. In addition, the symptoms, including dyspnoea and cough (which is severe, persistent, and dry in IPF), rob patients of their ability to breathe.


Our development pipeline

  • VP01 (C21) was granted orphan drug designation for IPF by the European Medicines Agency (EMA) in August 2016, and by the Food and Drug Administration (FDA) in the USA in January 2017. We are also targeting Pulmonary Arterial Hypertension (PAH) and COVID-19
  • VP02 is a novel formulation and delivery route for a pharmaceutically-active treatment for IPF and its associated severe cough, which is most often disabling and intractable.
  • VP03 includes new AT2R agonists
  • VP04 develops a digital therapeutic (DTx) for IPF

The drug candidates are also being investigated for their potential to treat other lung related disorders.